← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Detroit R & D, Inc.
Detroit, MI
$3,165,995
Total funding
7
Grants
Funding over time
peak $1.1M · FY2006–19$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$3,165,995 · 7
By mechanism
N01$1,149,968 · 2
N44$1,000,313 · 1
N43$446,617 · 2
R43$293,829 · 1
R44$275,268 · 1
Investigators at Detroit R & D, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
SBIR PHASE II: SITE-SPECIFIC ANTIBODIES FOR GLCNACYLATED PROTEINS IN CANCER$989,975
N44 · FY2013 · CA
New Award for SBIR Topic 103: Contractor: Detroit R&D: Contract No. TBD; route t$456,245
N01 · FY2009 · ES
New Award for SBIR Topic 103: Contractor: Detroit R&D: Contract No. TBD; route t$444,000
N01 · FY2008 · ES
IGF::OT::IGF R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)$299,097
N43 · FY2015 · CA
Targeted Antibody Microarrays:Tool for Toxicoproteomics$275,268
R44 · FY2006 · ES
SBIR Topic 97 - Multiplex Label-Free Nanowell Technology for Early Cardiotoxicity Biomarkers - Phase I$249,723
N01 · FY2016 · HL
Glycoproteins and Glycan-Binding IgGs: Biomarkers for Cancer and Inflammatory Di$152,936
R43 · FY2012 · CA
SBIR TOPIC 294 PHASE I - DEVELOPMENT OF GLYCOSYLATION-SPECIFIC RESEARCH REAGENTS$147,520
N43 · FY2011 · CA
Glycoproteins and Glycan-Binding IgGs: Biomarkers for Cancer and Inflammatory Di$140,893
R43 · FY2013 · CA
SBIR PHASE II: SITE-SPECIFIC ANTIBODIES FOR GLCNACYLATED PROTEINS IN CANCER$10,338
N44 · FY2019 · CA